PhaseBio Pharmaceuticals Current Part of Debt

Current Part of Debt of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Part of Debt growth rates and interactive chart. Current debt or short-term debt are a firm's financial obligations that are expected to be paid off within a year. It also includes the portion of long-term debt that is due within a year. It is a part of the overall indebtedness of a company, and is included in Debt/Equity and Debt/Assets ratios.


Highlights and Quick Summary

  • Current Part of Debt for the quarter ending September 29, 2021 was $5.88 Million (a 0.41% increase compared to previous quarter)
  • Year-over-year quarterly Current Part of Debt increased by 1.2%
  • Annual Current Part of Debt for 2020 was $5.81 Million (a 119.98% increase from previous year)
  • Annual Current Part of Debt for 2019 was $2.64 Million (a -79.44% decrease from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Part of Debt of PhaseBio Pharmaceuticals

Most recent Current Part of Debtof PHAS including historical data for past 10 years.

Interactive Chart of Current Part of Debt of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Current Part of Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $5.88 $5.86 $5.84
2020 $5.81 $5.79 $5.02 $3.69 $5.81
2019 $2.38 $1.99 $1.27 $0.42 $2.64
2018 $3.13
2017 $12.86

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.